Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness
Aziz Sheikh, Jim McMenamin, J. R. Taylor, et al.
The Lancet (2021) Vol. 397, Iss. 10293, pp. 2461-2462
Open Access | Times Cited: 997

Showing 1-25 of 997 citing articles:

Mechanisms of SARS-CoV-2 entry into cells
Cody B. Jackson, Michael Farzan, Bing Chen, et al.
Nature Reviews Molecular Cell Biology (2021) Vol. 23, Iss. 1, pp. 3-20
Open Access | Times Cited: 2410
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
Sara Y. Tartof, Jeff Slezak, Heidi Fischer, et al.
The Lancet (2021) Vol. 398, Iss. 10309, pp. 1407-1416
Open Access | Times Cited: 1166
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study
Tommy Nyberg, Neil M. Ferguson, Sophie Nash, et al.
The Lancet (2022) Vol. 399, Iss. 10332, pp. 1303-1312
Open Access | Times Cited: 1150
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Elisabetta Cameroni, John E. Bowen, Laura E. Rosen, et al.
Nature (2021) Vol. 602, Iss. 7898, pp. 664-670
Open Access | Times Cited: 1106
Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape
John S. Tregoning, Katie E. Flight, Sophie L. Higham, et al.
Nature reviews. Immunology (2021) Vol. 21, Iss. 10, pp. 626-636
Open Access | Times Cited: 1031
The biological and clinical significance of emerging SARS-CoV-2 variants
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Nature Reviews Genetics (2021) Vol. 22, Iss. 12, pp. 757-773
Open Access | Times Cited: 976
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
Thibault Fiolet, Yousra Kherabi, Conor-James MacDonald, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 202-221
Open Access | Times Cited: 820
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study
Anika Singanayagam, Seran Hakki, Jake Dunning, et al.
The Lancet Infectious Diseases (2021) Vol. 22, Iss. 2, pp. 183-195
Open Access | Times Cited: 753
SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo
Kenrie P. Y. Hui, John Chi Wang Ho, Man Chun Cheung, et al.
Nature (2022) Vol. 603, Iss. 7902, pp. 715-720
Open Access | Times Cited: 745
Waning Immunity after the BNT162b2 Vaccine in Israel
Yair Goldberg, Micha Mandel, Yinon M. Bar-On, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 24
Open Access | Times Cited: 669
Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant
Rigel Suzuki, Daichi Yamasoba, Izumi Kimura, et al.
Nature (2022) Vol. 603, Iss. 7902, pp. 700-705
Open Access | Times Cited: 616
Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity
Mark W. Tenforde, Wesley H. Self, Katherine Adams, et al.
JAMA (2021) Vol. 326, Iss. 20, pp. 2043-2043
Open Access | Times Cited: 586
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study
Adam S. Lauring, Mark W. Tenforde, James D. Chappell, et al.
BMJ (2022), pp. e069761-e069761
Open Access | Times Cited: 581
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
Hiam Chemaitelly, Patrick Tang, Mohammad R. Hasan, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 24
Open Access | Times Cited: 553
Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation
Akatsuki Saito, Takashi Irie, Rigel Suzuki, et al.
Nature (2021) Vol. 602, Iss. 7896, pp. 300-306
Open Access | Times Cited: 547
Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
Amarendra Pegu, Sarah O’Connell, Stephen D. Schmidt, et al.
Science (2021) Vol. 373, Iss. 6561, pp. 1372-1377
Open Access | Times Cited: 541
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
Koen B. Pouwels, Emma Pritchard, Philippa C. Matthews, et al.
Nature Medicine (2021) Vol. 27, Iss. 12, pp. 2127-2135
Open Access | Times Cited: 533
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study
Katherine A. Twohig, Tommy Nyberg, Asad Zaidi, et al.
The Lancet Infectious Diseases (2021) Vol. 22, Iss. 1, pp. 35-42
Open Access | Times Cited: 523
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study
Michela Antonelli, Rose Penfold, Jordi Merino, et al.
The Lancet Infectious Diseases (2021) Vol. 22, Iss. 1, pp. 43-55
Open Access | Times Cited: 466
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
Patrick Tang, Mohammad R. Hasan, Hiam Chemaitelly, et al.
Nature Medicine (2021) Vol. 27, Iss. 12, pp. 2136-2143
Open Access | Times Cited: 415
Spike-antibody waning after second dose of BNT162b2 or ChAdOx1
Madhumita Shrotri, Annalan M D Navaratnam, Vincent Nguyen, et al.
The Lancet (2021) Vol. 398, Iss. 10298, pp. 385-387
Open Access | Times Cited: 402
Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta)
Sean Wei Xiang Ong, Calvin J. Chiew, Li Wei Ang, et al.
Clinical Infectious Diseases (2021) Vol. 75, Iss. 1, pp. e1128-e1136
Open Access | Times Cited: 389
Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada
David N. Fisman, Ashleigh R. Tuite
Canadian Medical Association Journal (2021) Vol. 193, Iss. 42, pp. E1619-E1625
Open Access | Times Cited: 349
Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
Deborah Cromer, Megan Steain, Arnold Reynaldi, et al.
The Lancet Microbe (2021) Vol. 3, Iss. 1, pp. e52-e61
Open Access | Times Cited: 340
Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis
Qiao Liu, Chenyuan Qin, Min Liu, et al.
Infectious Diseases of Poverty (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 311
Page 1 - Next Page

Scroll to top